Skip to main content
. Author manuscript; available in PMC: 2016 Mar 3.
Published in final edited form as: Ann Rheum Dis. 2013 Apr 20;73(6):1060–1066. doi: 10.1136/annrheumdis-2012-202849

Figure 4.

Figure 4

Mortality of scleroderma (SSc) patients based on skin involvement subtype (A) and antibody status (B). Kaplan-Meier survival curves were analyzed from the time of SSc onset (first non-Raynaud's symptom). (C) Risk of mortality analyzed by Cox proportional hazards models.